Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Fleury sur Orne, France Clinical Trials

A listing of Fleury sur Orne, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (63) clinical trials

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are ...

Phase

2.36 miles

Learn More »

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Screening phase: New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic plateforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing). Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions ...

Phase

2.36 miles

Learn More »

SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer

SAFIR PI3K is an open-label multicenter phase II randomized trial, comparing alpelisib plus fulvestrant to maintenance chemotherapy in patient PIK3CA mutated with HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy. The primary objective is to determine whether treatment with ...

Phase

2.36 miles

Learn More »

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of locally advanced breast cancer representing approximately 5% of all breast cancers that requires immediate aggressive treatment. Significant progress has been made in recent years using a combination of treatments, including neoadjuvant chemotherapy, surgery and radiation therapy. Accumulating data ...

Phase

2.36 miles

Learn More »

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet ...

Phase

2.36 miles

Learn More »

Phase II Study of Regorafenib as Maintenance Therapy

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors: Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype Response to doxorubicin-based chemotherapy: partial response versus stable disease Centers The treatment will be administrated as long as it ...

Phase

2.36 miles

Learn More »

Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

This study will compare the clinical activity of novel immune-oncology agents (in combination or as single agents) to standard of care in participants with relapsed/refractory advanced NSCLC. The study will initially evaluate two treatment regimens/arms. Additional regimens/arms may be added via future protocol amendment(s). Participants will be stratified by histology ...

Phase

2.36 miles

Learn More »

Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Phase

2.36 miles

Learn More »

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group. PREVENE (PREemptive VENEtoclax) trial.

Phase

2.36 miles

Learn More »

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells. The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab administered after R-CHOP debulking therapy in patients with Richter Syndrome ...

Phase

2.36 miles

Learn More »